Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2012 1
2013 2
2014 2
2015 4
2016 1
2017 3
2018 2
2019 1
2020 2
2021 6
2022 1
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Dorman SE, et al. Among authors: narunsky k. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. N Engl J Med. 2021. PMID: 33951360 Free PMC article. Clinical Trial.
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis.
Stemkens R, Jager Vd, Dawson R, Diacon AH, Narunsky K, Padayachee SD, Boeree MJ, van Beek SW, Colbers A, Coenen MJH, Svensson EM, Fuhr U, Phillips PPJ, Te Brake LHM, Aarnoutse RE; PanACEA consortium. Stemkens R, et al. Among authors: narunsky k. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0068323. doi: 10.1128/aac.00683-23. Epub 2023 Sep 28. Antimicrob Agents Chemother. 2023. PMID: 37768317 Free PMC article.
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
Dooley KE, Hendricks B, Gupte N, Barnes G, Narunsky K, Whitelaw C, Smit T, Ignatius EH, Friedman A, Dorman SE, Dawson R; Assessing Pretomanid for Tuberculosis (APT) Study Team. Dooley KE, et al. Among authors: narunsky k. Am J Respir Crit Care Med. 2023 Apr 1;207(7):929-935. doi: 10.1164/rccm.202208-1475OC. Am J Respir Crit Care Med. 2023. PMID: 36455068 Clinical Trial.
Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832.
Dawson R, Diacon AH, Narunsky K, De Jager VR, Stinson KW, Zhang X, Liu Y, Hafkin J. Dawson R, et al. Among authors: narunsky k. Antimicrob Agents Chemother. 2023 Jun 15;67(6):e0147722. doi: 10.1128/aac.01477-22. Epub 2023 May 23. Antimicrob Agents Chemother. 2023. PMID: 37219453 Free PMC article. Clinical Trial.
Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials.
Musisi E, Wyness A, Eldirdiri S, Dombay E, Mtafya B, Ntinginya NE, Heinrich N, Kibiki GS, Hoelscher M, Boeree M, Aarnoutse R, Gillespie SH, Sabiiti W; PanACEA consortium. Musisi E, et al. Lancet Microbe. 2023 Nov;4(11):e913-e922. doi: 10.1016/S2666-5247(23)00191-X. Epub 2023 Oct 10. Lancet Microbe. 2023. PMID: 37832571 Free article.
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg-1 rifampicin.
Te Brake LHM, de Jager V, Narunsky K, Vanker N, Svensson EM, Phillips PPJ, Gillespie SH, Heinrich N, Hoelscher M, Dawson R, Diacon AH, Aarnoutse RE, Boeree MJ; PanACEA Consortium. Te Brake LHM, et al. Among authors: narunsky k. Eur Respir J. 2021 Jul 8;58(1):2000955. doi: 10.1183/13993003.00955-2020. Print 2021 Jul. Eur Respir J. 2021. PMID: 33542056 Free PMC article.
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ; REMoxTB Consortium. Gillespie SH, et al. N Engl J Med. 2014 Oct 23;371(17):1577-87. doi: 10.1056/NEJMoa1407426. Epub 2014 Sep 7. N Engl J Med. 2014. PMID: 25196020 Free PMC article. Clinical Trial.
High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis.
Kim S, Wu X, Hughes MD, Upton C, Narunsky K, Mendoza-Ticona A, Khajenoori S, Gonzales P, Badal-Faesen S, Shenje J, Omoz-Oarhe A, Rouzier V, Garcia-Prats AJ, Demers AM, Naini L, Smith E, Churchyard G, Swindells S, Shah NS, Gupta A, Hesseling AC; ACTG A5300/IMPAACT 2003/PHOENix Feasibility Study Team. Kim S, et al. Among authors: narunsky k. Pediatr Infect Dis J. 2022 May 1;41(5):e194-e202. doi: 10.1097/INF.0000000000003505. Pediatr Infect Dis J. 2022. PMID: 35239624 Free PMC article.
Resistance to Mycobacterium tuberculosis Infection Among Household Contacts: A Multinational Study.
Baliashvili D, Gandhi NR, Kim S, Hughes M, Mave V, Mendoza-Ticona A, Gonzales P, Narunsky K, Selvamuthu P, Badal-Faesen S, Upton C, Naini L, Smith E, Gupta A, Churchyard G, Swindells S, Hesseling A, Shah NS. Baliashvili D, et al. Among authors: narunsky k. Clin Infect Dis. 2021 Sep 15;73(6):1037-1045. doi: 10.1093/cid/ciab269. Clin Infect Dis. 2021. PMID: 33772550 Free PMC article.
A Step toward an Optimized Rifampin Dose Completed.
Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE. Boeree MJ, et al. Among authors: narunsky k. Am J Respir Crit Care Med. 2015 Aug 15;192(4):525-6. doi: 10.1164/rccm.201506-1061LE. Am J Respir Crit Care Med. 2015. PMID: 26278799 No abstract available.
30 results